Singapore - English - HSA (Health Sciences Authority)

apex pharma marketing pte. ltd. - palonosetron hydrochloride eqv palonosetron - injection, solution - palonosetron hydrochloride eqv palonosetron 0.25mg/5ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

flynn pharma ltd - palonosetron hydrochloride - solution for injection - 50microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

fresenius kabi ltd - palonosetron hydrochloride - solution for injection - 50microgram/1ml

United States - English - NLM (National Library of Medicine)

helsinn therapeutics (u.s.), inc. - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - aloxi injection is indicated in adults for prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). - acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (hec). - postoperative nausea and vomiting (ponv) for up to 24 hours following surgery. efficacy beyond 24 hours has not been demonstrated. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, aloxi is recommended even where the incidence of postoperative nausea and/or vomiting is low. aloxi injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: - acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly e

Kenya - English - Pharmacy and Poisons Board

beacon medicare limited 9/b/2, toyenbee circular road, motijheel, - palonosetron hydrochloride inn - injection - palonosetron 0.075mg - palonosetron

Israel - English - Ministry of Health

a.l. medi-market ltd. - palonosetron as hydrochloride - solution for injection - palonosetron as hydrochloride 50 mcg / 1 ml - palonosetron - palonosetron seacross is indicated in adults and in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - palonosetron hydrochloride - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - palonosetron hydrochloride - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nipro corporation - palonosetron hydrochloride - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

okayama taiho pharmaceutical co., ltd. - palonosetron hydrochloride - injection